PentaBase is a knowledge-based Danish pharmacogenomics company founded and managed by researchers and located in the heart of Denmark. We specialize in custom oligonucleotide production and development of in vitro diagnostic assays for real-time PCR with special focus on detection of somatic mutations in cancer. For more than 10 years, PentaBase has created products for researchers and medical professionals exploring new treatments and helping patients worldwide.
Our products are based on our proprietary technology, Intercalating Nucleic Acids (INAs®), giving our products unique abilities in analysis and manipulation of genetic material. These features are used by medical professionals and researchers to help treat diseases and acquire new knowledge. We believe in open-platform designs and strive to make our products compatible with basic instruments used in molecular biology facilities around the world.
Our visions are:
■ To enable detection of treatable diseases as early as possible
■ To broaden and improve the use of personalized treatment of genetic diseases and cancer
■ To reduce the number of false negative samples by improving sensitivity and reducing complexity of genetic analyses
We are continuously working with researchers and the research community to develop new products, and are always open for new collaborations. If you have a challenge in genetic analysis, then talk to us.
We strive to use our proprietary DNA technologies and our knowledge about real-time PCR to offer our customers the best service possible. We strive to combine fast delivery of superior quality products with optimal support before, during and after the purchase.
We believe in helping the next generation of pioneers and we prioritize a close relationship with local biotech research communities for the benefit of all. Our collaboration with the research communities is a valuable way of getting access to the newest knowledge and to find candidates for positions at PentaBase.
Innovation and creativity are central parts of our organization and we consider ourselves front-runners within innovations for real-time PCR applications. We are continuously using our general knowledge about real-time PCR and our proprietary DNA technologies to develop new products that either improve or disrupt existing technologies.